Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.
Discover the booming healthcare investment landscape as USD 115 billion flows into the sector, fueled by AI innovation, the ...
Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...
This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...
Weight-loss drugs like Ozempic are difficult to access without cash, but is the answer to really to roll these out on the NHS ...
GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long ...
Trump deals with Eli Lilly and Novo Nordisk increase access to obesity drugs, providing a safe, convenient way to slim down ...
The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? Investors will be watching what Trump makes happen.
Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...
17h
Weight loss jabs like Ozempic and Mounjaro 'linked to 170 deaths' - including adults in their 20s
Experts today sounded an alarm over the death toll as millions more are in line to get the jabs to curb the nation's bulging ...
A new study from the University of California San Diego has found that popular diabetes and weight-loss medications might ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback